Orna Therapeutics to Acquire ReNAgade Therapeutics

Orna Therapeutics to Acquire ReNAgade Therapeutics

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
Critical industry insight and formidable strength across key practices.

On May 23, Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNA®), announced its acquisition of ReNAgade Therapeutics, a pioneer in unlocking the potential of RNA therapeutics that demonstrated industry-leading delivery to multiple extra-hepatic cells in non-human primate (NHP) models over the past 18 months. The partnership will combine Orna and ReNAgade’s technological capabilities to drive R&D that is uniquely focused on circular RNA therapeutics.

The WilmerHale team advising Orna Therapeutics was led by Rosemary Reilly and Mark Nylen, and included Rebecca Nauta, Joe Odegaard, Nick Andreacchi, Bill Caporizzo, Meghan Walsh, Amy Null, Jenna Ventorino and Senior Paralegal Cindy Sullivan. 

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel